NICE gives final approval for IBS drug eluxadoline

NICE gives final approval for IBS drug eluxadoline PharmacoEconomics & Outcomes News 784, p34 - 12 Aug 2017 NICE gives final approval for IBS drug eluxadoline NICE has approved the drug, eluxadoline [Truberzi; Allergan] for routine funding on the NHS to treat patients with irritable bowel syndrome and diarrhoea (IBS-D) who have not responded to, or are cannot take other treatments. Truberzi will be available alongside existing drug and psychological treatments for IBS-D, including drugs that stop spasms in the gut or hypnotherapy. NICE has recommended that Truberzi only be offered in secondary care providing it is stopped after 4 weeks if the treatment is not working. "IBS-D can significantly impact a person’s quality of life, sometimes leading to anxiety and affecting their daily activities. The committee heard that having this treatment available when others no longer work will be welcomed by patients", said Director of the Centre for Health Technology Evaluation at NICE, Professor Carole Longson. NICE. GBP3 a day drug for irritable bowel syndrome gets NICE approval. Media Release : 27 Jul 2017. Available from: URL: http://www.nice.org.uk 809220392 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

NICE gives final approval for IBS drug eluxadoline

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/nice-gives-final-approval-for-ibs-drug-eluxadoline-HQ28rrZUH6
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4245-8
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p34 - 12 Aug 2017 NICE gives final approval for IBS drug eluxadoline NICE has approved the drug, eluxadoline [Truberzi; Allergan] for routine funding on the NHS to treat patients with irritable bowel syndrome and diarrhoea (IBS-D) who have not responded to, or are cannot take other treatments. Truberzi will be available alongside existing drug and psychological treatments for IBS-D, including drugs that stop spasms in the gut or hypnotherapy. NICE has recommended that Truberzi only be offered in secondary care providing it is stopped after 4 weeks if the treatment is not working. "IBS-D can significantly impact a person’s quality of life, sometimes leading to anxiety and affecting their daily activities. The committee heard that having this treatment available when others no longer work will be welcomed by patients", said Director of the Centre for Health Technology Evaluation at NICE, Professor Carole Longson. NICE. GBP3 a day drug for irritable bowel syndrome gets NICE approval. Media Release : 27 Jul 2017. Available from: URL: http://www.nice.org.uk 809220392 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off